icon-folder.gif   Conference Reports for NATAP  
 
  14th European AIDS Conference
Oct 16-19 2013
Brussels, Belgium
Back grey_arrow_rt.gif
 
 
 
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (STB) Has Durable Efficacy and Differentiated Safety Compared to Atazanavir Boosted by Ritonavir Plus Emtricitabine/Tenofovir DF in Treatment-na´ve HIV-1 Infected Patients: Week 144 Results
 
 
  Reported by Jules Levin
14th European AIDS Conference
October 16-19, 2013, Brussels, Belgium
 
N Clumeck1, J-M Molina2, K Henry3, J Gathe4, JK Rockstroh5, E DeJesus6, X Wei7, K White7, M Fordyce7, MS Rhee7, J Szwarcberg7
1St Pierre University Hospital, Brussels, Belgium; 2Saint Louis Hospital, Paris, France; 3Hennepin County Medical Center, Minneapolis, MN, US; 4Therapeutic Concepts P.A., Houston, TX, US; 5University of Bonn, Bonn, Germany; 6Orlando Immunology Center, Orlando, FL, US; 7Gilead Sciences, Foster City, CA, US

EACS1.gif

EACS2.gif

EACS3.gif

EACS4.gif

EACS5.gif

EACS6.gif

EACS7.gif

EACS8.gif

EACS9.gif

EACS10.gif

EACS11.gif

EACS12.gif

EACS13.gif

EACS14.gif